← Back to Search

Beta-blocker

Timolol 0.25% Ophthalmic Solution for Wound Healing

Phase 2
Waitlist Available
Led By Keith G LeBlanc, MD
Research Sponsored by Keith G. LeBlanc, Jr, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
skin wounds greater than or equal to 4cm, closed primarily and linearly following standard excision or Mohs
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months after suture removal
Awards & highlights

Study Summary

This trial will test whether using 0.25% timolol, a topical beta-blocker, can promote wound healing in people with linear wounds longer than 4 cm.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months after suture removal
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months after suture removal for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Observed cosmetic difference of scar in treatment side versus control: Yes or no

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: TimololExperimental Treatment1 Intervention
Timolol 0.25% applied to distal or posterior half of wound edge twice daily prior and adjunct to prior wound care.
Group II: Standard Wound CarePlacebo Group1 Intervention
Petrolatum ointment

Find a Location

Who is running the clinical trial?

Keith G. LeBlanc, Jr, MDLead Sponsor
Keith G LeBlanc, MDPrincipal InvestigatorLSU HSC New Orleans

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~7 spots leftby Apr 2025